OBJECTIVE: Daily provision of pregnant patients with dietary supplements containing antioxidants and phytonutrients, if initiated in the first trimester of pregnancy and continued throughout the gestation, may significantly decrease the incidence of preeclampsia. STUDY DESIGN: We conducted a single center, randomized, placebo-controlled investigation in which women were randomized by their risk status and assigned to daily ingestion of a supplement consisting primarily of a blended fruit and vegetable juice powder concentrate or placebo. RESULT: Of the 684 patients randomized to the trial, 267 (39.0%) completed it. The final analysis is based on those participants who completed the study. For the primary outcome of preeclampsia, there was no difference observed between the phytonutrient supplement group and the placebo group: 15.9% vs 16.3%, respectively, (R.R. 0.97 (0.56-1.69)). Non-significant trends toward lower placenta-related obstetrical complications were observed in the supplement group compared with the placebo cohort (8.3% vs 15.5%, respectively, (R.R. 0.57 (0.29-1.14). Those infants born to mothers taking the supplement in the high-risk stratified group demonstrated non-significant trends toward lower rates of respiratory distress syndrome (RDS); 5.3% in the supplement group vs 15.4% in the placebo group: R.R. 0.34 (0.12-1.01). CONCLUSION: Initiation of antioxidant/phytonutrient supplementation in the first trimester did not decrease rates of preeclampsia. Non-significant trends toward lower incidences of placental derived morbidity in those mothers taking the supplement in addition to decreased rates of RDS in infants born to supplemented mothers considered to be high-risk for preeclampsia, warrant further investigation.
INTRODUCTION
Mounting evidence in laboratory animals and humans indicates that embryonic tissues are extremely sensitive to oxygen tension and oxygen-free radical generation. 1 Investigators have determined that there is remarkably little, if any, blood flow in the human placenta before 10-12 weeks of gestation due to the plugging of sub-placental maternal arteries by placental tissue aggregates. [2] [3] [4] [5] Plasma filtrates rather than whole blood containing red cells appear to support the developing gestation until the end of the first trimester. Thus, embryonic and early placental development probably takes place at a low oxygen concentration. Data from Jauniaux et al. 6 reveal that in a normal pregnancy, by 10-12 weeks of gestation, the onset of maternal blood flow in the placenta results in increased oxygen tension and parallels an elevation in the expression and activity of the antioxidant enzymes. 6 This rise in oxygen tension within the placenta coincides with a metabolic transition from anaerobic to aerobic, which leads to increased production of reactive oxygen species.
As the intimacy between the maternal and fetal circulations increases during the last weeks of the first trimester, the placenta and embryo may be susceptible to oxygen-free radical species. 7 Detoxification by local antioxidant enzymes must occur in order to avoid tissue damage. 8 Based on this aforementioned knowledge, it is possible that failure of the developing gestation to have enough available stores of antioxidants to counteract the adverse effects of chronic oxidative stress could lead to injury with subsequent degeneration of syncytiotrophoblasts and adverse pregnancy outcomes.
Daily provision of pregnant patients with antioxidant/phytonutrient supplements, if initiated in the first trimester, and continued throughout gestation, could eliminate or significantly decrease the severity of preeclampsia in maternal-fetal pairs. [9] [10] [11] [12] Moreover, other complications of pregnancy related to prematurity might benefit from this intervention as well and be significantly reduced in frequency.
reduce the effects of oxidative stress at the level of the placenta and the maternal vasculature, thus leading to significant reductions in the occurrence of preeclampsia. We also posited that we would observe decreases in pregnancy complications that were primarily related to inadequate placental development and support of the fetus including fetal growth restriction, preterm rupture of membranes, preterm labor and abruptio placenta. We chose the product Juice Plus þ as our supplement based on the knowledge that this phytonutrient product contains components in addition to vitamins C and E (described in methods section), which may provide a stronger mechanism of antioxidant defense. Juice Plus þ has been shown in previous investigations to be associated with a variety of potentially beneficial vascular effects including increased antioxidant activity, folate levels, decreased homocysteine levels, vasodilatory effects, improvement in cholesterol profiles, positive effect on blood pressures and decreased calcium deposition in coronary arteries. [14] [15] [16] The only study that we are aware of that compares vitamins C and E to Juice Plus þ was an investigation evaluating exercise induced muscle breakdown and oxidative stress in which no significant differences were observed. 17 
METHODS

Study design and patient selection
The Preeclampsia Prevention trial was a single center, randomized, placebo-controlled, parallel group investigation performed through the University of Mississippi Medical Center (UMMC). The UMMC IRB committee approved the study, which was subsequently registered at clinicaltrials.gov (NCT00583635). Women were recruited from the UMMC inpatient and outpatient areas including the OB Associates Practice of private patients, and the Jackson Medical Mall Obstetric clinics of high-risk and low-risk patients. Recruitment of patients occurred between May 2004 and December 2010. The last baby was delivered in June 2011. Randomization was stratified to low and high-risk groups. Low-risk group inclusion criteria included the following: nulliparous or multiparous patients with a singleton gestation and no evidence of systemic vascular disease (hypertension, diabetes mellitus, connective tissue disease, inherited/acquired thrombophilia).
High-risk group inclusion criteria included: multiparous patients with a singleton gestation and a prior history of preeclampsia (prior eclampsia, prior mild or severe preeclampsia, prior HELLP (hemolysis, elevated liver enzymes and low platelet syndrome) syndrome), or nulliparous or multiparous patients with a singleton gestation with a documented history of chronic hypertension, diabetes mellitus, connective tissue disease or inherited/acquired thrombophilia. Exclusion criteria included any patients that did not meet inclusion criteria or elected to decline participation after informed consent. All patients in both the low and highrisk groups were enrolled and initiation of the supplement or placebo had occurred by the end of the 12th week of gestation.
Randomization and masking
Once consent was obtained, the patient's information was presented to the UMMC Pharmacy who controlled drug dispensing and patient assignment. Participants were randomly allocated in a 1:1 ratio to receive the supplement or matched placebo daily from before the 12th week of gestation until delivery. The randomization sequence was stratified by risk group (low or high) with balanced blocks of 8 and was held by the UMMC pharmacy. Participants and providers were blinded to patient intervention assignment; our biostatistician broke the code only for the planned interim and the final analyses without revealing any specific assignment information to others. After randomization, patients received an unmarked bottle of capsules with either the product or the placebo. For purposes of clarity, the terms 'product', 'supplement', 'phytonutrient', and 'antioxidant' are equivalent and will be used interchangeably in reference to the active supplement that was provided.
The placebo capsule contents consisted of microcrystalline cellulose, with an equivalent appearance to the active capsules. The phytonutrient/ antioxidant supplement capsule contents consisted of a blended fruit and vegetable juice powder concentrate derived from acerola cherry, apple, beet, broccoli, cabbage, carrot, cranberry, kale, orange, peach, papaya, parsley, pineapple, spinach and tomato (Juice Plus þ Orchard and Garden Blends, NSA, LLC, Collierville, TN), with each capsule providing B7.5 mg beta-carotene, 234 mg vitamin C, 30 mg vitamin E in the form of RRRalpha-tocopherol, 420 mg folate and 60 mg calcium as previously described. 18 
Procedures
Participants were instructed to take two capsules twice daily until delivery, and to leave unused capsules in the bottles. Patients were instructed to follow their habitual diet and to continue taking any prescribed medications, iron supplements or prenatal vitamins. Our compliance measure involved tabulation of residual capsules by our research nurses at each subsequent outpatient visit. An additional 28 capsules were placed in each of the bottles to account for patients that would possibly miss or reschedule an appointment. The physician that was taking care of the patient on that particular day made management decisions regarding the frequency and interval of subsequent appointments.
Statistical analysis
Data were recorded at the end of each pregnancy and entered into a relational database by the research nurses assigned to the study and analyzed by our local biostatistician (WM).
The primary outcome was a 66% reduction in the incidence of preeclampsia from the UMMC baseline of B10% down to 3.3%. Data from a study of the UMMC patient population in the mid-1990s was the basis for an estimated 10% prevalence of preeclampsia in the combined low-and high-risk UMMC patient population. 19 The estimated sample size to find a 66% decrease was 245 completed pregnancies per group (total ¼ 490) with 80% power at the nominal 5% level of significance. Owing to concern for significant patient attrition, it was estimated that an additional 200 participants would need to be recruited. Secondary outcomes included evaluation of the incidence of second and third trimester pregnancy loss as well as the incidence of preterm labor, premature rupture of membranes, placental abruption, fetal growth restriction (unrelated to infection or chromosomal abnormality) and neonatal outcomes (birthweight, APGAR scores, small for gestational age (GA), neonatal demise, neonatal intensive care unit (NICU) admission, respiratory distress syndrome (RDS), need for assisted ventilation, intraventricular hemorrhage and seizure activity o24 h of life).
Results for continuous variables are reported as means±s.d. for distributions that appear relatively symmetric and as medians (range) otherwise. Results for categorical variables are reported as proportions. Comparisons between the two treatment arms were made using appropriate tests for the scale of measurement and included independent samples t-tests, Mann-Whitney, w 2 and Fisher's exact test. For purposes of the analysis, the study remained blinded to the data analyst until results were reported to the investigators.
Funding source NSA, LLC provided funding for the entire investigation and had no role in the study design, data collection, data analysis or data interpretation. Additionally, this company supplied none of the authors with income or other types of supplemental funding. Figure 1 provides the flow diagram of our trial profile. Of those who were considered for enrollment into the study (n ¼ 690), group assignment was not available for 6 subjects so 684 were randomized to receive product or placebo. There were 335 (49.0%) randomized to the placebo group and 349 (51.0%) randomized to the supplement group. Of the 684 who underwent randomization, 267 (39.0%) completed the study. Among the 417 (61.0%) who did not complete the study, 379 (91%) withdrew from the study and 29 (7%) were lost-to-follow-up, while 9 (2%) were ineligible after randomization.
RESULTS
We performed an analysis comparing the demographics of those women who completed the study compared with those that did not (data not shown). There is some evidence that women who completed the study were slightly older (average age of 27.1) than those who did not (average age of 24.8). There was also a small difference in the percentage of African-Americans who completed the study (70%) vs those who did not (78.7%). Importantly, however, there was not a difference, regarding ethnicity, in assignment to the placebo (48%-did not complete vs 50.6%-completed) or supplement (52%-did not complete; 49.4%-completed) groups. Therefore, we proceeded with the analysis under the assumption that missing data were non-informative. The final analysis is based on those participants who completed the study (n ¼ 267). Of these, 50.6% (n ¼ 135) were randomly assigned to the placebo group and 49.4% (n ¼ 132) were randomly assigned to the supplement group. Table 1 depicts the demographics of the phytonutrient supplement and placebo groups, respectively. The two groups are well balanced for all demographic variables with the exception of a slight difference in age in addition to an increased incidence of prior preterm birth in the placebo group. When analyzing our primary outcome (Table 2) , the incidence of preeclampsia, no difference was observed between the phytonutrient group and the placebo group: 15.9% vs 16.3%, respectively, (R.R. 0.97 (95% CI, 0.56-1.69)). When the different categories of preeclampsia were examined (that is, mild, severe, superimposed, [HELLP syndrome, eclampsia), there were no significant differences observed between the two groups. Table 3 demonstrates our evaluation of the primary outcome based on risk stratification (that is, low risk vs high risk), which exhibited no differences in the incidence of preeclampsia between the low-risk groups (phytonutrient À 10.7% vs placebo-8.8%; R.R. 1.22 (95% CI, 0.40-3.77)) or the high-risk groups (phytonutrient À 19.7% vs placebo-21.9%; R.R. 0.91 (95% CI, 0.49-1.68)).
Investigation of placenta-related obstetric morbidity (composite analysis of preterm, premature rupture of membranes, preterm delivery, placental abruption, intrauterine growth restriction, pregnancy loss 414 weeks) (Table 4) , revealed trends toward a decreased incidence of these outcomes in the phytonutrient group compared with the placebo cohort (8.3% vs 15.5%, respectively, (R.R. 0.57 (0.29-1.14) but results were not statistically significant. Neonatal outcomes (Table 5 ) also revealed no significant differences in outcomes, although we did observe a non-significant trend toward a lower incidence in NICU admissions and neonatal respiratory complications in the phytonutrient supplement group. This trend in lower NICU admissions and neonatal respiratory complications in the phytonutrient group approached statistical significance when these outcomes were interrogated in the high-risk group of patients. Table 6 shows the rate of NICU admission to be 5.3% vs 15.4% in the phytonutrient and the placebo groups, respectively; R.R. 0.34 (95% CI, 0.12-1.01), and the proportion of newborns diagnosed with RDS was 5.3% in the phytonutrient group vs 15.4% in the placebo group; R.R. 0.34 (95% CI, 0.12-1.01). The infants born to the higher risk mothers who were assigned to the phytonutrient group were observed to have greater average birth weights (2990 g±542 g) compared with the newborns in the maternal placebo group (2752 g±913; P ¼ 0.05).
COMMENT Preeclampsia has been considered to be a multi-staged human disorder as outlined by Roberts and others. [20] [21] [22] [23] One component of the pathophysiology appears to be first and early second trimester oxidative stress in the placenta of genetically susceptible maternal-fetal pairs that later is translated into advanced stages of diffuse maternal endothelial cell dysfunction and multi-organ disease. [24] [25] [26] Diseases related to endothelial damage, such as diabetes mellitus and chronic hypertension, appear to further predispose women to preeclampsia. 27, 28 Just as there are several stages to the development of preeclampsia, there may be multiple important epochs during pregnancy when an adequate response to oxidative stress must be present to avert the subsequent development of preeclampsia. [20] [21] [22] [23] 29 One of these important periods appears to be the first trimester during which time placentation occurs, and a later event may occur in the second half of pregnancy when most patients with preeclampsia express their disease. There may be times between these early and late stages that can set into motion factors leading to the development of preeclampsia. Such a period Phytonutrient and preeclampsia prevention trial MR Parrish et al of time has been described as the early second trimester when vascular remodeling and decidualization of the spiral arterioles is supposed to occur. 30, 31 An inadequate response to oxidative stress would be expected to result in impaired endothelial dependent vasodilatation that would yield an increase in maternal blood pressure, similar to processes observed in patients with renalvascular hypertension. 32 On the basis of this fundamental knowledge, we formulated the hypothesis that early supplementation of the maternal diet with a fruit and vegetable juice powder concentrate known to contain multiple sources of antioxidants and phytonutrients, would reduce the incidence and severity of preeclampsia. Based on the pathophysiology of other adverse pregnancy outcomes, we also hoped to observe reductions in perinatal mortality and morbidity secondary to preterm rupture of membranes, preterm labor, placental pathology and fetal growth restriction.
Before, and after the initiation of our study, multiple trials investigating vitamins C and E have been published and demonstrated no beneficial effect in regard to lowering the incidence of preeclampsia. [33] [34] [35] [36] [37] [38] [39] However, as these publications were reviewed, it was evident that one of the commonalities enveloping these trials was that they all had an average GA at the time of randomization of 413 weeks, with the majority of them having an average GA 415 weeks. Our study was unique in that all of our patients were enrolled and taking their treatments during the first trimester (average GA of 9 weeks). We believed the first trimester encompassed an important transition that involves an increase in oxygen tension at the level of the placenta that coincides with potential adverse placental-embryonic effects from increased production of oxidative radicals. 6, 7 Another important difference between our study and the others is that we utilized a source of antioxidants and phytonutrients derived from fruits and vegetables, which we posited could have more of an impact compared with vitamins C and E alone. Despite our study's earlier initiation of treatment, we discovered that the incidence of preeclampsia was not affected positively or negatively with the addition of a phytonutrient. We did observe statistically Phytonutrient and preeclampsia prevention trial MR Parrish et al non-significant trends toward decreased rates of placental derived morbidity (that is, preterm, premature rupture of membranes, preterm labor, placental abruption, intrauterine growth restriction), which may have yielded significant results if the study had been powered to evaluate these outcomes. However, these trends may have been altered by the fact that the baseline history of preterm delivery in the placebo group was significantly higher compared were the treatment group. One of the limitations of our investigation was the poor completion rate by the enrolled participants, which also led to our final analysis being performed on only those participants who completed the trial. The poor completion rate was anticipated during the development phase of our project and therefore we increased our sample size by an additional 200 patients. Despite this adjustment being made, only 39% of those enrolled and randomized completed the study. This can be explained in part by the difficulty many of these patients had taking the capsules around the time of pregnancy when nausea and vomiting are very prevalent. Another explanation is that many patients do not have insurance established before their first visit and often have to seek initial obstetrical care through the University Medical System. The majority of these women eventually receive Medicaid benefits and then seek obstetrical care elsewhere based on location, convenience or both. Many study participants were also lost when the primary prenatal care site for patients was changed. However, as noted in our results section, we did compare the demographics of those who completed and those who did not complete the study and no significant differences were observed. Therefore, we felt it prudent to proceed with study analysis under the assumption that missing data were non-informative. Additional limitations include the lack of external validity for other institutions. The majority of those enrolled in both groups were African-American, and therefore our results should be interpreted with caution in areas where other ethnicities may be more predominant.
Strengths of our study include the fact that all of our patients were enrolled and the administration of product or placebo was initiated during the first trimester in addition to our methods of compliance encouragement and assessment provided by our diligent research nursing staff. Our secondary findings regarding non-significant trends toward lower rates of placental derived morbidity in the phytonutrient cohort warrants further evaluation. Additionally, our observation of higher birth weights, decreased rates of NICU admissions and a lower incidence of RDS in infants born to our high-risk patients taking the phytonutrient should also be investigated further. Rumbold et al. 38 also observed a lower rate of RDS, albeit in a different cohort of women. The protective effect of antioxidants is biologically plausible based on the known oxidative contributions to the pathophysiology of RDS. 38, 40 If this finding is confirmed to be legitimate, it could be an important finding since the risk for premature delivery and subsequent risks for neonatal morbidity in this subset of women is inevitably higher.
Although underpowered, we felt that it was important to present the findings from our 7-year study. We believe that it contributes further to the available literature demonstrating that antioxidants do not appear to prevent preeclampsia, even if the supplement is initiated exclusively during the first trimester. The question remains, however, why the majority of investigations known at this time have failed to demonstrate a benefit of antioxidant therapy despite a plethora of in vitro and in vivo literature suggesting oxidative stress as one of the pathophysiological mechanisms of preeclampsia. It may be that only a certain subset of women are susceptible to oxidative stress due to preexisting deficiencies in maternal antioxidant nutrients as alluded to by Mikhail et al. 41 and these women may be more likely to demonstrate advantageous results as previously demonstrated by Rumiris et al. 42 Thus, future research should focus on adequately powered investigations evaluating the initiation of antioxidant supplementation in the first trimester and also consider the effect of antioxidants when initiated in the pre-conceptual period. These types of research will continue to be important as we strive to better understand the mechanisms of preeclampsia in addition to discovering potential therapies that may decrease the incidence of this unique pregnancy related disorder. Phytonutrient and preeclampsia prevention trial MR Parrish et al
